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Abstract  285 
We examined common variation in asthma risk by conducting the largest meta-analysis to date 286 
of asthma genome-wide association studies (23,948 cases, 118,538 controls) from multi-287 
ancestry populations. We identified five new asthma loci, uncovered two novel associations at 288 
two known asthma loci, established asthma associations at two loci implicated previously in 289 
comorbidity of asthma plus hay fever, and confirmed nine known loci. Investigation of 290 
pleiotropy showed large overlaps in genetic variants with autoimmune and inflammatory 291 
diseases. Enrichment of asthma loci near enhancer marks, especially in immune cells, suggests 292 
a major role of these loci in the regulation of immune-related mechanisms.  293 
  294 
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Asthma is a complex disease that affects hundreds of millions of people worldwide. The 295 
prevalence of asthma varies between populations and ethnicities, ranging in the U.S. from 3.9% 296 
in Mexican Americans to 12.5% in African Americans1. The contribution of genetic factors to 297 
asthma risk has been demonstrated in family studies, where heritability estimates range from 298 
25% to 80%2. The large variability in prevalence and heritability estimates reflects the 299 
significant role of environmental exposures on disease risk and the considerable phenotypic 300 
heterogeneity that is a hallmark of this disease. These features largely explain why genome-301 
wide association studies (GWAS) of asthma have uncovered a smaller number of loci than 302 
similarly sized studies of other multifactorial diseases3. Indeed, up to now, only 21 loci have 303 
been associated with asthma per se in 20 studies, and these loci explain only part of the genetic 304 
risk. Moreover, an exome-chip study of EVE consortium samples showed no evidence for 305 
large-effect of low frequency or rare variants in asthma risk4. This lack of rare variants in asthma 306 
is similar to findings from other common diseases5,6. To generate larger sample sizes for GWAS 307 
meta-analysis of asthma enabling the discovery of novel risk loci, we established the Trans-308 
National Asthma Genetic Consortium (TAGC) across worldwide groups of investigators with 309 
genome-wide data. The TAGC sample of more than 142,000 individuals representing diverse 310 
ancestry allowed us to construct a comprehensive catalog of asthma risk variants that are robust 311 
across populations and environmental exposures. By combining TAGC meta-analysis results 312 
with existing databases, we have been able to assess the genetic architecture of asthma risk 313 
alleles with respect to functional effects and shared effects with other diseases. 314 
 315 
RESULTS 316 
Meta-analysis of asthma GWAS from ethnically diverse populations 317 
We combined data from asthma GWAS with high-density genotyped and imputed SNP data 318 
(2.93 million SNPs) in the following populations: European-ancestry (19,954 cases, 107,715 319 
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controls), African-ancestry (2,149 cases, 6,055 controls), Japanese (1,239 cases, 3,976 controls) 320 
and Latino (606 cases, 792 controls) (Supplementary Table 1). After extensive QC of summary 321 
data provided by each participating group (Online Methods, Supplementary Note and 322 
Supplementary Table 2), we first conducted ancestry-specific meta-analyses followed by a 323 
multi-ancestry meta-analysis of all populations (23,948 cases, 118,538 controls) to identify 324 
additional loci with pan-ancestry effects. As childhood-onset asthma may be distinct from later-325 
onset asthma7 and may represent a more homogeneous subgroup, we also performed analyses 326 
on the pediatric subgroup (asthma onset ≤16 years; 8,976 cases, 18,399 controls). All meta-327 
analyses were performed using both fixed-effects (significance summarized in Pfixed) and 328 
random-effects (Prandom). For all results, we employed a stringent Prandom (or Pfixed) threshold of 329 
10-8 to define genome-wide significance. As results were consistent between methods regarding 330 
the detection of loci with at least one SNP significantly associated with asthma, we present the 331 
results from the random-effects analysis for the European-ancestry and multi-ancestry meta-332 
analyses which include a large number of studies allowing an accurate estimate of the between- 333 
study variance and results from the fixed-effects analysis for the African-ancestry, Japanese 334 
and Latino meta-analyses (including at most seven studies). We observed little evidence of 335 
inflation in the test statistics in either the ancestry-specific (lambda: European-ancestry, 1.031; 336 
African-ancestry, 1.014; Japanese, 1.021; Latino, 1.044) or multi-ancestry (lambda=1.046) 337 
meta-analyses (Supplementary Fig.1).  338 
We identified 523 genome-wide significant SNPs (Prandom≤10-8) at 14 loci in European-339 
ancestry populations (Fig.1, Table 1, Supplementary Tables 3 and 4; see definition of a locus 340 
in Online Methods). No genome-wide significant risk loci were detected in ancestry-specific 341 
analyses within the African-ancestry, Japanese or Latino populations (Supplementary Fig.2 and 342 
Supplementary Tables 5-7), possibly due to a lack of power. In the combined multi-ancestry 343 
meta-analysis, 90 additional SNPs of which 20 belonged to four additional regions were 344 
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significant at Prandom≤10−8 (Fig.2, Table 1, and Supplementary Tables 3 and 8). Altogether, the 345 
18 chromosomal regions included: five new loci associated with asthma at 5q31.3, 6p22.1, 346 
6q15, 12q13.3, 17q21.33, two new significant associations at 6p21.33 and 10p14 that were 347 
independent from previously reported signals at these loci in ancestry-specific populations 348 
(Latino8 and Japanese9), two reported associations with the phenotype asthma plus hay fever at 349 
8q21.13 and 16p13.13 in one European-ancestry study10, and nine previously identified asthma 350 
loci. The two asthma plus hay fever signals on 8q21.13 and 16p13.13 were not detected with 351 
asthma alone in the previous study10; in the current study, the 8q21.13 locus reached genome-352 
wide significance only in the multi-ancestry analysis. None of the lead SNPs at these 18 loci 353 
showed evidence for heterogeneity in effect sizes across studies except for the lead variant at 354 
9p24.1 (Phet for Cochran’s Q test11=0.008 across European-ancestry studies and Phet=0.02 355 
across multi-ancestry studies, Table 1, Supplementary Fig.3). Heterogeneity in the ancestry-356 
specific effect sizes of the lead SNPs was only detected at the 6p22.1 and 6p21.33 loci (Pethnic 357 
for heterogeneity between the four ancestry-specific odds-ratios equal to 0.003 for rs1233578 358 
at 6p22.1 and to 0.02 for rs3131064 at 6p21.33), where the lead SNPs were only significant in 359 
European-ancestry populations (Supplementary Table 3). The meta-analysis of the pediatric 360 
subgroup showed strong evidence for association at five of the 18 loci (2q12, 5q31 and 17q12-361 
21 having Prandom≤10-8; 6p21.33 and 9p24.1 having Prandom≤5x10-8) (Supplementary Figs.4 and 362 
5 and Supplementary Table 9). No novel loci specific to that group were identified.  363 
Besides the detection of new signals, our GWAS provided genome-wide significant 364 
confirmation of nine previously reported loci both in European-ancestry and multi-ancestry 365 
meta-analyses (Table 1; Supplementary Fig.6). It is of note that the lead SNP (rs2952156) at 366 
the 17q12-21 locus is within ERBB2 (Prandom=2.2x10-30 in multi-ancestry meta-analysis), which 367 
is at least 180kb from published asthma-associated signals within the GSDMB/ORMDL3 368 
haplotype block3 (Supplementary Fig.7). This is due to effect size heterogeneity across studies 369 
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(0.001≤Phet≤0.05) that extends over a 200kb region spanning ORMDL3 and GSDMB 370 
(Supplementary Table 10). This heterogeneity is partly due to age of onset of asthma, as 371 
previously reported7. Indeed, in the pediatric group, the 17q12-21 SNPs did not show 372 
heterogeneity (Phet≥0.09) and the lead SNP rs8069176 is 3.6 kb proximal to GSDMB 373 
(Prandom=Pfixed=4.4 x10-26). This is supported by the comparison in SNP effect size between 374 
pediatric and non-pediatric studies which shows a significant difference for rs8069176 375 
(Phet=7.4x10-4) but no difference for rs2952156 (Phet=0.11). The two SNPs, rs2952156 and 376 
rs8069176, are in moderate LD (r2=0.30). Interestingly, both SNPs are in strong LD (r2>0.9) 377 
with missense variants that lie in ERBB2 (for the proxy of rs2952156) and in ZPBP2 and 378 
GSDMB (for the proxies of rs8069176). In addition, rs2952156 and rs8069176 are associated 379 
with GSDMB and ORMDL3 expression in five blood e-QTL databases12-15 and with expression 380 
of GSDMA, CDK12, GSDMB, ORMDL3 in lung14,16. However, only rs2952156 is associated 381 
with PGAP3 transcript in lung14,16 (Supplementary Table 11a). Further exploration of eQTL 382 
data from GTEx14, which includes both blood and lung samples, indicated that rs8069176 383 
accounted for a large part of the association of the most significant SNP with ORMDL3 384 
transcript in blood while rs2952156 accounted for a large part of the association of the most 385 
significant SNP with PGAP3 transcript in lung (Supplementary Table 11b). This suggests that 386 
the asthma-associated signals near PGAP3/ERBB2 and ORMDL3/GSDMB blocks may affect 387 
asthma risk through the expression of different genes in different tissues, as also suggested in a 388 
study of lung epithelial cells17. However, these results need to be confirmed in additional 389 
samples and integration of genotypic, gene expression and epigenetic data may bring further 390 
insight into the mechanisms underlying asthma risk at this locus.  391 
Finally, out of the 21 published asthma loci, 12 loci were not confirmed by this study 392 
(Supplementary Table 12). The strongest asthma-associated SNP at each of these non-replicated 393 
loci, as reported in the GWAS catalog3, had P-values ranging between 0.99 and 8.5x10-7 in our 394 
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meta-analyses. The non-replication of these loci is due to the following reasons: (i) three loci 395 
were found in a study with small sample size and the SNPs had very low allele frequency18; (ii) 396 
four loci were ancestry-specific4,9,19; (iii) three loci were detected in studies with a small number 397 
of cases (<1,200 subjects) at the discovery stage20-22. For the other two loci reported in 398 
European-ancestry studies23,24, IL6R rs4129267 and IL2RB rs2284033 (Prandom= 8.5x10-7 and 399 
7.9 x10-5 in multi-ancestry meta-analysis) had their P-values dropping to 0.01 and 0.08 400 
respectively after removing the datasets of the initial publications23,24.  401 
 To investigate whether the 18 asthma loci identified in this study contain multiple 402 
distinct signals, we performed approximate conditional regression analysis based on summary 403 
statistics for all loci, except for the 9p24.1 region which showed heterogeneity in SNP effect 404 
size across studies over the whole locus. For the 17q12-21 locus, this analysis was restricted to 405 
the pediatric sub-group in which there was no heterogeneity. This analysis was based on 406 
summary statistics of European-ancestry fixed-effects meta-analysis, using the Genome-wide 407 
Complex Trait Analysis (GCTA) software25 (Online Methods). After conditioning on the lead 408 
SNP in each investigated region, four secondary signals (2q12, 5q22.1, 5q31, 6p21.32) 409 
remained genome-wide significant (Pfixed≤10-8) after conditioning on the lead SNP 410 
(Supplementary Table 13), thus resulting in 22 distinct genome-wide significant signals 411 
identified by this study. 412 
To provide biological insight into our findings, we conducted a comprehensive 413 
bioinformatic assessment of the asthma association signals using several resources. First, to 414 
pinpoint the most likely candidate genes at the nine loci harboring novel associations with 415 
asthma per se, we interrogated results of six eQTL studies in tissues relevant to asthma,  blood 416 
(including peripheral blood13,14, lymphoblastoid cell lines (LCLs)12,15, monocytes26) and whole 417 
lung tissue14,16. This e-QTL investigation was complemented by the search for missense 418 
variants potentially tagged by the association signals. To assess the level of overlap of asthma 419 
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associations with susceptibility loci for other phenotypes, we next interrogated the GWAS 420 
catalog3 while varying the strength of association with asthma (thresholds from 10-8 to 10-3). 421 
To get better insight on how asthma associated variants may functionally influence disease, we 422 
then interrogated the ROADMAP/ENCODE functional genomics data generated in a wide 423 
range of human cell types27. Finally, the degree of connectivity between the asthma-associated 424 
loci was assessed through text mining28. Results from these analyses are described in the 425 
following sections. 426 
 427 
Potential candidate genes at the nine loci harboring novel associations with asthma  428 
A summary of eQTL analysis for these nine loci is described in Table 2 and Supplementary 429 
Table 14. 430 
New asthma susceptibility loci  431 
Five new loci were identified in the current study. The strongest new signal in both European-432 
ancestry (Prandom=8.6x10-13) and multi-ancestry (Prandom=2.2x10-12) meta-analyses was with 433 
SNP rs2325291 in the intron of BACH2 at 6q15 (Fig.1d), which is strongly correlated with 434 
rs10455168 (r2=0.91), a cis-eQTL altering expression of BACH2 in blood13. BACH2 encodes a 435 
zip transcription factor that is a key regulator of nucleic acid-triggered antiviral responses in 436 
human cells29. The second strongest signal was with rs17637472 (Prandom=3.3x10-9 and 6.6x10-437 
9 in European-ancestry and multi-ancestry analyses), which lies between ZNF652 and PHB at  438 
17q21.33 (Fig.1f), and is a strong cis-eQTL for GNGT2 (173kb from rs17637472) in 439 
blood12,13,15,26. GNGT2 was shown to interact with beta-Arrestin 1 to promote G-protein-440 
dependent Akt signaling for NF-kappaB activation30. Among the other new signals, the lead 441 
SNP rs1233578 at 6p22.1 (Prandom=5.3x10-9 in European-ancestry populations) resides between 442 
TRIM27 and GPX5 (Fig.1b). No cis-eQTL was identified at this locus. Notably, TRIM27 was 443 
reported to be a negative regulator of CD4 T cells31 and to negatively regulate signaling 444 
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mediated by NOD2, a protein involved in antimicrobial responses32 and a key innate immune 445 
receptor in inflammation. The 12q13.3 lead SNP (rs167769), which was only significant in the 446 
multi-ancestry analysis (Prandom=3.9x10-9), lies in an intron of STAT6 (Fig.2e) and is strongly 447 
associated with STAT6 expression in blood12,13,15 and lung16. STAT6 is a transcription factor 448 
that is essential for the functional responses of Th2 lymphocytes mediated by IL-4 and IL-1333. 449 
This result robustly establishes the association of STAT6 with asthma risk that has been disputed 450 
by candidate gene studies34. The 5q31.3 lead SNP rs7705042 (Prandom=7.9x10-9 in multi-451 
ancestry analysis) is within an intron of NDFIP1 (Fig.2b) and associated with NDFIP1 452 
expression in blood13,15. NDFIP1 is a potent inhibitor of antiviral response35 and inflammation 453 
processes36.  454 
Novel signals at loci previously associated with asthma in ancestry-specific populations  455 
Two associations in our study were with novel SNPs at loci previously reported to be associated 456 
with asthma in Latinos8 and Japanese9. The first one, located at 6p21.33, was reported in an 457 
admixture mapping study in Latinos8. The lead SNP in our study, rs3131064, intergenic 458 
between IER3 and DDR1 (Fig.1c), only reached significance in European-ancestry populations 459 
(Prandom=2.6x10-10) and was not correlated (r2=0) with any of the SNPs reported under the Latino 460 
admixture peak. The 6p21.33 region is gene rich, with many genes whose transcripts are 461 
associated with our asthma signals, including IER3, FLOT1, VARS2, MICB, HLA-C, MICA in 462 
blood12-15,26 and CDSN, TUBB, HLA-A, AGPAT1, HLA-C and MICA in lung14,16 463 
(Supplementary Table 14). Of these genes, MICA, MICB and HLA-Class I genes are known to 464 
be involved in immune-related mechanisms. This 6p21.33 locus is more than 600 kb apart from 465 
the previously reported 6p21.32 locus that spans HLA-Class II genes. Intensive sequencing 466 
efforts and imputation of HLA classical alleles, which requires access to the raw genotype data, 467 
are needed to dissect the whole HLA region. The second association at a known locus was at 468 
10p14 (Fig.2d), where a GWAS in Japanese9 reported association with adult asthma (lead SNP 469 
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rs10508372). We detected a new signal that reached significance only in the multi-ancestry 470 
meta-analysis (rs2589561; Prandom=3.5×10−9) and was not correlated with rs10508372 in both 471 
European-ancestry and Japanese populations. The SNP rs2589561 is in a gene desert, 929 kb 472 
distal of GATA3. By using recently published promoter capture Hi-C data in hematopoietic 473 
cells37, we found that two proxies of rs2589561 (r2>0.9) lie in a region interacting with GATA3 474 
promoter, especially in immune CD4+T cells. This result and the function of GATA3 protein, 475 
a transcription factor that is a master regulator of differentiation of Th2 cells and innate 476 
lymphoid cells type 238, make GATA3 an excellent candidate for asthma risk. 477 
Asthma signals previously reported for asthma plus hay fever 478 
Loci on chromosomes 8q21.13 and 16p13.13 were previously associated with the comorbid 479 
phenotype of asthma plus hay fever but not with asthma alone in one European-ancestry study10. 480 
In our study, the 8q21.13 lead SNP rs12543811 (Prandom=1.1x10-10 in the multi-ancestry 481 
analysis) lies between TPD52 and ZBTB10 (Fig.2c) and is in strong LD (r2=0.79) with the 482 
previously reported asthma/hay fever SNP rs7009110. These two SNPs represent the same 483 
signal, as the association with rs12543811 becomes non-significant after conditioning on 484 
rs7009110. Thus, the 8q21.13 locus is likely to be implicated in allergic asthma. A functional 485 
analysis of the asthma/hay fever locus pinpointed PAG1 as a promising candidate39. The 486 
chromosome 16p13.13 SNP rs17806299 is within an intron of CLEC16A (Fig.1e; 487 
Prandom=2.1x10-10 and 2.7x10-10 in European-ancestry and multi-ancestry meta-analyses) and in 488 
moderate LD (r2=0.66) with the previously reported asthma/hay fever signal (rs62026376 in 489 
CLEC16A)10. However, the association of asthma with rs17806299 was completely removed 490 
after conditioning on rs12935657, a SNP present in our data and having r2=0.96 with 491 
rs62026376, indicating that these SNPs represent the same signal and 16p13.13 is probably also 492 
an allergic asthma locus. The SNP rs17806299 is strongly associated with the expression of a 493 
nearby gene, DEXI in blood13,26. Similar observations of associations of CLEC16A SNPs with 494 
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autoimmune diseases and expression of DEXI together with chromosome conformation capture 495 
experiments implicated DEXI as the most likely candidate gene for autoimmune diseases40. The 496 
potential relevance of DEXI in allergic diseases has also been previously discussed10.  497 
 It is of note that all the lead SNPs at the nine new asthma-associated loci lie in non-coding 498 
regions and were not found in linkage disequilibrium (LD; r2≥0.8) with missense variants.  499 
 500 
Overlap of asthma associations with susceptibility loci for other phenotypes  501 
We next explored whether the nine loci that harbored new signals for asthma per se overlapped 502 
with GWAS loci reported for allergy-related phenotypes, lung function phenotypes, or other 503 
immune-related diseases using the GWAS catalog3. Six of these nine asthma loci showed 504 
overlapping associations with allergy-related phenotypes and eight of them with auto-immune 505 
diseases and infection-related phenotypes (Table 2). The 6p21.33 locus which harbors HLA-506 
Class I genes, had the greatest number of overlapping associations, which reflects the density 507 
of immune genes in that region. Moreover, three asthma loci overlapped with associations with 508 
lung function phenotypes.  509 
We then expanded our search of overlap between the asthma association signals having 510 
multi-ancestry Prandom<10-4 in this study and GWAS signals with all phenotypes and diseases 511 
in the GWAS catalog3. We examined 4,231 unique trait-loci combinations after applying a 512 
filtering process (Online Methods). We used the disease classification from Wang et al.41 to 513 
group traits in the GWAS catalog. We summarized the overlap of GWAS catalog signals with 514 
asthma signals by the proportion of catalog SNPs having asthma P-values smaller than 10-4 in 515 
our analysis. This revealed significant overlap with autoimmune disease (10%, i.e. 49 out of 516 
480 catalog SNPs show evidence for asthma association), consistent with the hypothesized 517 
shared susceptibility42, moderate overlap with diseases having an inflammatory component 518 
(cardiovascular diseases, cancers, neuro-psychiatric diseases), and small to no overlap with 519 
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other diseases (Table 3). When investigating specific diseases and traits (Supplementary Table 520 
15), the most significant overlap is with allergic phenotypes including atopic dermatitis. There 521 
is little to no overlap with other phenotypes that appear most frequent in the GWAS catalog 522 
(for example, there are no common associations with type 2 diabetes, Supplementary Table 15). 523 
 When we examined an even larger set of SNPs in the GWAS catalog (those that show an 524 
association with asthma at Prandom≤10-3 in our multi-ancestry meta-analysis), additional 525 
interesting pleiotropic signals emerged (Supplementary Table 16). In this analysis, we used a 526 
less stringent significance threshold to provide a larger set of candidate genes for future asthma 527 
studies and for pleiotropy analysis of asthma and diseases sharing genetic associations. This 528 
larger set of associations paints a more complete picture of asthma risk, revealing a wide range 529 
of pleiotropic effects for a number of traits, ranging from lung cancer and multiple sclerosis 530 
with rs3817963 in BTNL2, to schizophrenia and autism spectrum disorder with rs7914558 in 531 
CNNM2. Finally, this analysis generated an extended set of asthma candidate genes. Indeed, 532 
there are 210 SNPs in the GWAS catalog that are associated with asthma in our dataset at this 533 
association threshold of 10-3. We estimated that the proportion of false positives among these 534 
is smaller than 1%. The most interesting signals are those with SNPs implicating novel 535 
pleiotropic asthma genes; for example, rs1464510 (Prandom=2.2x10-5) in the LPP gene at 3q28 536 
that was previously implicated in vitiligo and celiac disease.  537 
 538 
Relationship between asthma associated genetic variants and epigenetic marks of gene 539 
regulation 540 
Because nearly all lead SNPs at the 18 loci identified by this study lie in non-coding sequences, 541 
except for the missense variant (rs20541) within IL13, we investigated whether the asthma-542 
associated variants and their proxies (r2≥0.80) were concentrated in cis-regulatory DNA 543 
elements to get greater insight into their potential functional role. We interrogated the integrated 544 
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functional data from 111 ROADMAP and 16 ENCODE reference epigenomes in a wide range 545 
of human cell types27. We focused on histone marks characterizing enhancers and promoters 546 
assayed in all 127 epigenomes and DNase I hypersensitivity sites available in 51 cell types. To 547 
assess enrichment of the asthma risk variants for co-localization with these regulatory elements, 548 
we used the Uncovering Enrichment through Simulation pipeline43. This approach first consists 549 
of generating random sets of SNPs, from the SNP panel used for analysis, that match to the 550 
characteristics of the original asthma-associated SNPs (distance from the nearest transcription 551 
start site, number of LD partners, minor allele frequency). The SNP data (original and random 552 
sets of SNPs and their LD partners) are then intersected with the cell-specific epigenome  tracks 553 
of regulatory elements using IntersectBed44 to determine which SNPs co-localize with a given 554 
type of regulatory elements in a track. For each track, the empirical P-value for enrichment is 555 
equal to the number of instances when the frequency of co-localization of the random SNP sets 556 
with a regulatory feature is greater than or equal to the frequency of the co-localization of the 557 
original asthma-associated SNP set with that feature divided by the number of random SNPs 558 
sets generated (here, 10,000). Benjamini-Hochberg false discovery rates (FDRs) were 559 
computed from these empirical P-values to correct for multiple testing (Online Methods). Only 560 
16 out the 18 identified asthma loci were explored because we excluded the two loci spanning 561 
the HLA region due to the large amount of variability and extensive LD in this region. While 562 
asthma-associated variants were strongly enriched for co-localization with enhancer marks, 563 
there was only weak enrichment in promoter marks (Table 4 and Supplementary Table 17). 564 
This enrichment was slightly more pronounced when active enhancer states were examined 565 
separately from all active and inactive enhancer states. This enrichment was highest in 566 
leukocytes (27 leukocytes of which 19 (70%) are lymphocytes and monocytes). For example, 567 
a FDR≤5% for enrichment of asthma loci in active enhancers was observed in 100% of 568 
leukocytes compared to 50% of all cell types, and similarly for enrichment in both active and 569 
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inactive enhancers (FDR≤ 5% in 89% of leukocytes and in 43% of all cell types) (Table 4). The 570 
enrichment of asthma risk variants for co-localization with DNAse I hypersensitivity sites was 571 
intermediate between the enrichments in promoters and enhancers and was again increased in 572 
blood cells (FDR≤5% in 40% of leukocytes and 12% of all cell types) (Table 4 and 573 
Supplementary Table 18). The strong enrichment of asthma loci in enhancer marks, especially 574 
in immune cells, indicates that the associated genetic variants are likely involved in regulation 575 
of immune-related functions. This also suggests that epigenetic mechanisms may be key to 576 
promoting asthma, as evidenced for IgE levels, an asthma-associated phenotype45.  577 
 578 
Connectivity between asthma-associated loci  579 
To characterize the degree of connectivity between genes located at the 18 asthma-associated 580 
loci, we applied the Gene Relationships Across Implicated Loci (GRAIL) text-mining 581 
approach28. Eleven genes showed significant similarity to genes in other associated loci at 582 
PGRAIL<0.05 (7 of them being highly connected with PGRAIL<10-3) (Fig.3 and Supplementary 583 
Table 19). These genes were connected by keywords such as ‘asthma’, ‘allergy’, ‘atopic’, 584 
‘interleukin’, ‘cytokines’, ‘airway’, and ‘inflammation’, which confirms the central role of 585 
immune-related mechanisms accounting for these connections.  586 
  587 
Discussion  588 
We present here the largest genome-wide association study of asthma in subjects of European-589 
ancestry and in ancestry-diverse subjects. We discovered nine novel loci influencing asthma 590 
risk, using a stringent threshold of 10-8 for genome-wide significance. This study confirms that 591 
immune-related mechanisms are prominent in the etiology of asthma, but also brings novel 592 
insights that open new routes for future asthma research. Indeed, our data show that all the 593 
asthma-associated loci identified by this study are enriched in enhancer marks and are thus 594 
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likely to be involved in gene regulation. This study also highlights that the best candidates at a 595 
number of loci are involved in immune response to viruses or bacteria, which underlines the 596 
importance of infections in asthma risk. It further provides evidence for overlap of asthma loci 597 
with loci underlying other diseases that have an inflammatory component, such as 598 
cardiovascular diseases, cancers and neuro-psychiatric diseases. These collective findings both 599 
expand our current understanding of the genetic architecture of asthma as well as provide a 600 
more comprehensive resource for future genetic and epigenetic studies of asthma and further 601 
investigation of the mechanisms underlying the pleiotropic effects of genetic variants on asthma 602 
and a broad range of multifactorial diseases. 603 
This study, which doubles the number of cases from the previous largest genome-wide 604 
studies23,24, identified 613 SNPs that correspond to 22 distinct association signals at 18 loci that 605 
met criteria for genome-wide significance in European-ancestry or multi-ancestry populations. 606 
Pooling data from ethnically-diverse populations can increase power to detect new loci (four 607 
loci reached the genome-wide threshold only in the multi-ancestry analysis) but may also 608 
increase heterogeneity (two loci were only detected in European-ancestry populations). If we 609 
assume an asthma prevalence of 10%, the variance in liability to asthma explained by the 22 610 
genome-wide significant variants of this  study was estimated to be 3.5% (95% Confidence 611 
Interval: 2.0%-5.4%) of which 72% was accounted for by the known loci and 28% by the new 612 
loci.  613 
The overall relative paucity of asthma risk loci detected by large-scale GWAS compared 614 
to other common diseases may be due to the clinical heterogeneity of asthma and the important 615 
role of differing environmental exposures. It is recognized that asthma is not a single disease 616 
but that the syndrome encompasses consistent groupings of various characteristics46, including 617 
age of asthma onset, the severity of disease, occupational exposures and the varying response 618 
to treatment. Other subtypes may be defined by the character of the inflammatory infiltrate 619 
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(eosinophilic or neutrophilic). It is thus possible that additional asthma loci will be revealed by 620 
studies targeting more specific asthma sub-phenotypes and/or taking into account 621 
environmental exposures. 622 
The enrichment of the asthma loci identified by this study in enhancer marks, mainly in 623 
lymphocytes and monocytes, suggests that the underlying causal variants may modify the gene 624 
regulatory landscape in immune cells. However, known asthma genes (IL1RL1, TSLP, IL33, 625 
ORMDL3/GSDMB) are expressed in the airway epithelium where they contribute to modulating 626 
airway inflammation. Investigation of epigenetic marks in airway epithelial cells may bring 627 
additional insight. The involvement of several genes (BACH2, NDFIP1 or genes within HLA), 628 
at the identified loci, in immune response to viruses provides additional evidence for a potential  629 
modulating effect of asthma-associated SNPs on the association of asthma with respiratory viral 630 
infections, as reported at the 17q12-21 locus47-49. The overlap of asthma-associated loci with 631 
those underlying a broad range of diseases strengthens the growing importance of pleiotropy in 632 
multifactorial diseases. 633 
In conclusion, future discoveries might come by exploring more complex models of 634 
asthma phenotypes and through the joint analysis of asthma and other immune-mediated and 635 
inflammatory diseases. The central role of gene regulatory mechanisms highlighted by our 636 
study might prompt genome-wide explorations of the epigenome while integrating information 637 
on genetic variation and environmental exposure histories.  638 
 639 
URLs 640 
National Human Genome Research Institute (NHGRI) and European Bioinformatics Institute 641 
(EBI) catalog of published genome-wide association, https://www.ebi.ac.uk/gwas/; 1000 642 
Genomes Project Consortium Phase 3, http://www.internationalgenome.org/; Genome-wide 643 
Complex Trait Analysis (GCTA), http://www.complextraitgenomics.com/software/gcta; 644 
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Blood-eQTL database, http://genenetwork.nl/bloodeqtlbrowser/; GTEx, 645 
http://www.gtexportal.org/; MuTHER database, http://www.muther.ac.uk/; eQTL database in 646 
lymphoblastoïd cell lines from MRCA and MRCE families, 647 
https://www.hsph.harvard.edu/liming-liang/software/eqtl/; GHS_Express, 648 
http://genecanvas.ecgene.net/uploads; ROADMAP and ENDCODE epigenomics data, 649 
http://egg2.wustl.edu/roadmap/web_portal/; Uncovering Enrichment through Simulation 650 
(UES) pipeline, https://github.com/JamesHayes/uesEnrichment; GRAIl,, 651 
https://www.broadinstitute.org/ mpg/grail/; VIZGRAIL, 652 
http://software.broadinstitute.org/mpg/grail/vizgrail.html, LocusZoom, 653 
http://locuszoom.sph.umich.edu/ locuszoom/ 654 
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ONLINE METHODS  656 
 657 
GWAS Studies and Data Shared 658 
All 66 genome-wide association studies that form the TAGC consortium are described in the 659 
Supplementary Note and summarized in Supplementary Table 1. These studies included 56 660 
studies of European-ancestry (19,954 cases, 107,715 controls), seven studies of African-661 
ancestry (2,149 cases, 6,055 controls), two Japanese studies (1,239 cases, 3,976 controls) and 662 
one Latino study (606 cases, 792 controls), making a total of 23,948 cases and 118,538 controls. 663 
There were 27 studies including only childhood-onset asthma (defined as asthma diagnosed at 664 
or before 16 years of age) which allowed us analyzing separately a pediatric subgroup (8,976 665 
cases, 18,399 controls). All subjects provided informed consent to participate in genetic studies 666 
and local ethics committees for each of the individual studies approved the study protocol. 667 
Definition of asthma was based on doctor’s diagnosis and/or standardized questionnaires (see 668 
Supplementary Note for details). The samples were genotyped on a variety of commercial 669 
arrays, detailed in the Supplementary Note and Supplementary Table 2. GWAS were performed 670 
on imputed SNP data that were generated using Hapmap2 as reference panel and one of the 671 
commonly used imputation software (Supplementary Note and Supplementary Table 2). In 672 
each dataset, the effect of each individual SNP on asthma, assuming an additive genetic model, 673 
was estimated through a logistic regression-based approach and expressed in terms of a 674 
regression coefficient with its standard error; the detailed methodology and software used for 675 
analysis by each study can be found in the Supplementary Note and Supplementary Table 2.   676 
 677 
Imputation, quality control (including adjustments for population stratification) and analysis 678 
was done by each group independently and data on a predefined set of 3,952,683 autosomal 679 
SNPs was shared. These SNPs were those of the HapMap Phase 2, release 21 panel in subjects 680 
from European, Asian and African-ancestry that were filtered using SNP annotation from the 681 
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build 37.3 of the reference sequence and dbSNP b135 (31,587 SNPs (0.8% of all SNPs) from 682 
previous annotations that showed discrepancies with the chosen annotation were deleted). The 683 
variables that were shared contained the study name, general information on SNPs (rs number, 684 
chromosome, position, alleles (baseline and effect alleles as used in the analysis by each study), 685 
SNP status (imputed or genotyped SNP and whether the SNP genotype or imputed value was 686 
used in computation), quality control (QC) indicators (call rate and P-value for Hardy-687 
Weinberg (HW) equilibrium test for genotyped SNPs, software used for imputation and 688 
imputation quality score for imputed SNPs), allele frequencies in cases and controls and 689 
information on association statistics (regression coefficient for SNP effect, standard error of 690 
regression coefficient, Z scores, P-values associated with Z score statistic). Association 691 
statistics for at least one SNP in at least one study were available for 2.93 million SNPs.  692 
 693 
Quality control of shared data 694 
For each SNP, the alleles on the Hapmap2 template (reference and alternate alleles on the 695 
positive strand) were compared to the alleles (baseline and effect alleles) used in the analysis 696 
by each group. When necessary, the association variables (allele frequencies, regression 697 
coefficient for SNP effect, Z score) were swapped to match the reference/alternate alleles of the 698 
template. Data for each SNP showing any ambiguity or error in assignment to the template were 699 
set to missing. In addition, a number of QC checks were done regarding the name, format, range 700 
of possible values for all shared variables mentioned in the previous paragraph as well as 701 
consistency checks across variables. Any problem or inconsistency was corrected, otherwise 702 
the data for that SNP were set to missing. Strict QC criteria were used for inclusion of a SNP 703 
in the analysis. When a SNP genotype was used in the study analysis, these criteria were: call 704 
rate ≥97%, P-value for HW test ≥10-6 and minor allele frequency (MAF) ≥0.01 in both controls 705 
and cases. When a SNP imputed value was used in the analysis, the criteria were: imputation 706 
     
28 
 
quality score ≥0.5 and MAF≥0.01 in both controls and cases. The distribution of the summary 707 
statistics (regression coefficient for SNP effect, standard error, Z score) of all SNPs passing QC 708 
was examined for each study; SNPs that still showed extreme Z scores (≥ 7 or ≤-7) after QC 709 
were excluded.  710 
 711 
Meta-analysis of GWAS 712 
We used both inverse variance fixed-effects and random-effects models when the meta-713 
analyses included a large number of studies (European-ancestry, multi-ancestry and pediatric 714 
sub-group meta-analyses), which allows an accurate estimate of the between-study variance 715 
based on the DerSimonian and Laird method50. We used a fixed-effects model for the meta-716 
analyses of the African-ancestry, Japanese and Latino populations, which included at most 717 
seven studies. For all these meta-analyses, we used the SNP regression coefficient and standard 718 
error from each study for which the SNP passed QC11. All meta-analyses were done with Stata® 719 
version 14.1 (STATA Corp., College Station, Texas, USA). To minimize the false-positive 720 
findings and to obtain robust results, we examined the combined results for SNPs for which at 721 
least two-thirds of the studies contributed to a meta-analysis. We applied a stringent threshold 722 
of Prandom (or Pfixed) of 10−8 to declare a SNP effect as genome-wide significant. This threshold, 723 
which is stricter than the standard threshold of 5x10-8, classically used in GWAS, allows 724 
minimizing the family-wise error rate. We checked that using the 5x10-8 threshold did not 725 
change the number of asthma-associated loci but only the list of significant SNPs at a locus.  726 
For each lead SNP, we defined a support interval around the lead SNP designated as “locus”; 727 
the bounds of this interval were the positions of the two most extreme SNPs among all SNPs 728 
lying on each side of the lead SNP and having Prandom (or Pfixed) ≤ 10-6 (i.e. SNPs with P-values 729 
within two orders of magnitude of the critical genome-wide significance threshold). In each 730 
meta-analysis, heterogeneity of per-SNP effect sizes across studies was assessed using the 731 
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Cochran’s Q statistic11. Heterogeneity between the four ethnic groups (European-ancestry, 732 
African-ancestry, Japanese and Latino) was also tested using the Cochran’s statistic applied to 733 
meta-analysed results obtained in each ethnic group and all groups combined.  734 
 735 
Conditional analysis of asthma-associated loci 736 
The Genome-wide Complex Trait Analysis (GCTA) software25 (see URL section) was used to 737 
perform approximate conditional analysis for all loci with at least one SNP reaching the 738 
genome-wide significance level. This approximate conditional analysis is based on the 739 
summary meta-analysis statistics obtained under a fixed-effects model and takes into account 740 
the correlations among SNPs, that are estimated from a large reference population included in 741 
the meta-analysis. Approximate conditional analysis was only carried out in the European-742 
ancestry ethnic group which can be assumed to share a similar LD pattern and represents the 743 
largest ancestry-specific dataset and the only one to show genome-wide significant results. As 744 
this analysis assumes no heterogeneity in SNP effect size across studies, loci showing evidence 745 
for heterogeneity (Phet≤0.05 based on the Cochran’s Q test) for a large portion of the locus were 746 
excluded. This was the case of the 9p24.1 locus that shows evidence for heterogeneity across 747 
the whole locus and the 17q12-21 locus where there is evidence for heterogeneity across a 200 748 
kb segment within that locus. However, there is no heterogeneity between studies at 17q12-21 749 
in the pediatric sub-group while there is still heterogeneity at 9p24.1 in this sub-group. 750 
Therefore, GCTA was applied to all 18 asthma-associated loci, shown in Table 1, except for 751 
9p24.1 and 17q12-21 loci, using summary statistics from the meta-analysis of all European-752 
ancestry studies. For the17q12-21 locus, this analysis was restricted to the European-ancestry 753 
pediatric sub-group. We used the large ECRHS (European Community Respiratory Health 754 
Survey) dataset as the reference sample to estimate LD. This dataset was genotyped using 755 
Illumina Human610Quad array, as part of the GABRIEL consortium, and included 2101 756 
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unrelated individuals after QC23. Imputation was done using the MACH software51 and 757 
Hapmap2, release 21 panel; only well-imputed SNPs (imputation quality score rsq>0.8) and 758 
with minor allele frequency (MAF) ≥1% were kept in this reference panel. For each asthma-759 
associated locus, the region explored by conditional analysis extended by 500 kb on each side 760 
of the two extreme SNPs defining the support interval around the lead SNP (see preceding 761 
paragraph). However, we reduced that extension to 250 kb for the 6p21.33 and 6p21.32 loci to 762 
avoid overlap. The length of the regions explored by conditional analysis varied from 1.01 Mb 763 
to 1.63 Mb. Within each investigated region by conditional analysis, fixed-effects summary 764 
meta-analysis data for SNPs belonging to that region were adjusted for the lead SNP using the 765 
--cojo-cond option. If there was an additional SNP meeting the Bonferroni-corrected threshold 766 
for the total number of SNPs overall all regions investigated by GCTA (P=4.1x10-6) after 767 
adjustment for the lead SNP, we performed an additional round including both SNPs. If the 768 
remaining SNPs had P-values greater than 4.1x10-6, no further analysis was performed. The 769 
results of this analysis are reported in Supplementary Table 13. 770 
 771 
Identification of cis-eQTLs at new asthma-associated loci 772 
To gain a better understanding of the potential genes driving the association signals at the novel 773 
asthma loci, we defined a list of SNPs to be interrogated that included the lead SNPs, the 774 
secondary signals identified by conditional analysis and all SNPs in LD with these SNPs (r2 775 
comprised between 0.5 and 1). To search for cis-expression quantitative trait loci (eQTLs) 776 
within at most 1 Mb of each investigated SNP, we interrogated six publically available eQTL 777 
databases by giving priority to cell types more likely to be involved in asthma biology (blood 778 
cell types and lung tissue): (i) a meta-analysis of the transcriptional profiles from peripheral 779 
blood cells of 5,311 Europeans (the blood eQTL browser13);(ii) the gene expression data of 777 780 
lymphoblastoïd cell lines (LCLs) from the MuTHER database12; (iii) the transcription profiles 781 
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of 405 and 550 lymphoblastoïd cell lines from UK asthma (MRCA) and eczema (MRCE) 782 
family members, respectively15; (iv) the eQTL data from monocytes of 1490 subjects included 783 
in the GH-express database26; (v) the GTEx eQTL Browser with data from multiple tissues 784 
including blood and lung14; (vi) the transcriptional profiles from lung tissues of 1111 subjects16. 785 
 786 
Identification of missense variants at asthma-associated loci 787 
To complement the eQTL analysis, we searched whether the lead asthma-associated SNPs and 788 
secondary signals were in strong LD (r2≥0.8) with missense variants using the HaploReg V4.1 789 
tool (see URL section). 790 
 791 
Overlap of asthma associations with susceptibility loci for other phenotypes 792 
Overlap of novel genome-wide significant asthma loci with associations with allergy-related 793 
phenotypes/diseases and immune-related diseases as well as lung function phenotypes was first 794 
annotated using the March 24, 2015 version of the NHGRI-EBI (National Human Genome 795 
Research Institute and European Bioinformatics Institute) GWAS catalog3 downloaded from 796 
https://www.ebi.ac.uk/gwas/. We then used this catalog to systematically investigate the 797 
overlap of asthma signals having Prandom ≤ 10-4 in the multi-ancestry meta-analysis with 798 
association signals of all diseases and traits in the catalog. That version of the catalog had 799 
19,080 SNP entries, and 16,047 of those SNPs had a TAGC asthma association P-value. To 800 
investigate pleiotropy, we filtered out SNPs associated with asthma in the database, SNPs that 801 
have a reported GWAS P-value larger than 10-7 (with the intent of removing some of the 802 
potential false positives in the catalog) and SNPs that are duplicated (i.e., remove disease-SNP 803 
duplications). This reduced the number of entries to 5,927. Note that this process did not remove 804 
SNPs in perfect LD associated with the same disease, nor SNPs that were present multiple times 805 
in the database as associated with different phenotypes. For some diseases or quantitative traits, 806 
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there were multiple SNPs in the same region reported in the catalog potentially yielding 807 
redundant information. Some of the SNPs could be in strong LD, but some could reflect 808 
independent signals. To avoid possible duplication of signals, we decided to keep only unique 809 
trait-loci combinations as reflected by the variables "Disease.Trait" and "Region" in the catalog. 810 
There were 4,231 unique entries left after this filtering step. Diseases/traits in the GWAS 811 
catalog were grouped using the classification from Wang et al. 41 We summarized the overlap 812 
of GWAS catalog signals with asthma signals by the proportion of catalog SNPs with asthma 813 
P-values smaller than 10-4 in our analysis. The significance of overlap was estimated by the 814 
binomial tail probability for observing the number of TAGC SNPs with Prandom≤10-4 among the 815 
number of SNPs reported in the GWAS catalog for a group of diseases. The significance 816 
threshold for enrichment in shared associations between a disease group and asthma was set 817 
equal to 0.05 divided by the number of disease groups investigated using a Bonferroni 818 
correction.  Finally, we examined a larger set of SNPs in the GWAS catalog that show an 819 
association with asthma at Prandom≤10-3 in TAGC multi-ancestry meta-analysis and estimated 820 
the proportion of false positives among those SNPs. 821 
 822 
 823 
Relationships between asthma associated genetic variants and epigenetic marks of gene 824 
regulation  825 
To get better insight into the functional role of the genetic variants at the novel and known 826 
asthma loci identified by this study, we investigated whether the lead SNPs and their proxies 827 
(r2≥0.80) were concentrated in cis-regulatory DNA elements. We used the Uncovering 828 
Enrichment through Simulation pipeline43 that was adapted to the current study. This approach  829 
tests if GWAS-identified SNPs are enriched in particular functional annotations through use of 830 
Monte Carlo simulations. The original set of asthma-associated SNPs  included the lead SNPs 831 
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at each locus (ie one SNP per asthma-associated locus, as recommended by Hayes et al43). We 832 
excluded the two associated loci that span the HLA region (6p21.33 and 6p21.32) because of 833 
the high amount of variability and LD in this region. Each of the original lead SNPs is 834 
categorized by its distance from the nearest transcription start site (TSS) and number of LD 835 
partners (r2≥0.8). Quartiles for both the TSS distance and LD partner count are calculated and 836 
the initial SNPs are binned accordingly. Then, SNPs from the whole set of imputed SNPs used 837 
for analysis are binned according to the original SNP criteria (distance from the closest TSS, 838 
number of LD partners, and also MAF). Random SNP sets are chosen, matching to the original 839 
bin frequencies. LD partners (r2>0.8) for both the original lead SNPs and random SNPs are 840 
retrieved. The SNP data, including the original and random sets of SNPs and their 841 
corresponding LD partners (r2≥0.8), are intersected with the cell-specific epigenome tracks of 842 
regulatory elements using the BedTool’s intersectBed44, to determine which SNPs co-localize 843 
with a  given type of regulatory elements (for example, enhancers or promoters) in a track. For 844 
each specific track, we computed an empirical-P value using 10,000 random SNP sets (this P-845 
value is equal to rloci/n where rloci is the number of instances when the frequency of co-846 
localization of the random SNP sets with the regulatory feature is greater than or equal to the 847 
frequency of co-localization of the original SNP set with that feature and n is the number of 848 
random SNP sets chosen (here, 10,000). We used the Benjamini-Hochberg false discovery rates 849 
(FDR) to correct for multiple testing. We interrogated the functional data from 111 ROADMAP 850 
reference epigenomes and 16 additional epigenomes from ENCODE (Encyclopedia of DNA 851 
elements) that are available in a wide range of human cell and tissue types27 (data downloaded 852 
from http://egg2.wustl.edu/roadmap/data/). We focused on enhancers and promoters that were 853 
defined using the 15-state model trained from the core set of five chromatin marks (H3K4me3, 854 
H3K4me1, H3K36me3, H3K27me3, H3K9me3) assayed in all 127 epigenomes. We also 855 
examined enrichment in DNase I hypersensitivity sites that are available in 51 cell types.  856 
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 857 
Connectivity between asthma-associated loci  858 
We used GRAIL (Gene Relationships Across Implicated Loci)28 to assess the relatedness 859 
between asthma associated loci. As described in detail previously28, to define the genes near 860 
each SNP, GRAIL finds the furthest neighboring SNPs in the 3′ and 5′ direction that are in LD 861 
(r2>0.5) and proceeds outward in each direction to the nearest recombination hotspot. All genes 862 
that overlap that interval are considered implicated by the SNP. If there are no genes in that 863 
region, the interval is extended by 250 kb in either direction. We took the lead SNPs at all 864 
asthma-associated loci identified by this study as a seed and queried loci to investigate 865 
biological connectivity among those loci. The relatedness between genes belonging to these 866 
loci was determined through text-mining of PubMed abstracts. Each individual gene at each 867 
locus was tested for significant enrichment in GRAIL connectivity to genes located at the other 868 
loci. The relationships between genes belonging to different loci that met the nominal threshold 869 
PGRAIl < 0.05 were visualized using VIZGRAIL52.  870 
 871 
Variance explained by the asthma associated genetic variants 872 
We estimated the variance in liability to asthma explained by the 22 distinct genome-wide 873 
significant SNPs (18 lead SNPs plus four secondary signals identified by approximate 874 
conditional analysis) at the 18 asthma-associated loci using a method based on the liability 875 
threshold model53 and assuming a prevalence of asthma of 10%. The variance in liability to 876 
asthma explained by individual SNPs was summed over all 22 significant variants. For the loci 877 
that included two SNPs (lead SNP and secondary signal), we used the SNP effect sizes 878 
estimated by approximate joint analysis using GCTA25. We also estimated the variance in 879 
liability to asthma explained by the nine lead SNPs at the nine new asthma loci and by the 13 880 
distinct genome-wide significant signals at the nine known loci. 881 
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Data availability 883 
At time of submission, the summary statistics for association of SNPs with asthma that support 884 
the findings of this study are available to the Editor and reviewers from the corresponding 885 
author upon request. The summary statistics of the meta-analysis that support the findings of 886 
this study will be made publically available through a link from the GWAS entry catalog for 887 
the TAGC study on the EBI (European Bioinformatics Institute) web site 888 
(https://www.ebi.ac.uk/gwas/downloads/summary-statistics) as soon as the paper is accepted 889 
for publication. 890 
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 Table 1 Genetic loci associated with asthma in European-ancestry and multi-ancestry meta-analyses  
             European-ancestry meta-analysis    Multi-ancestry meta-analysis 
 
Pethnick Regiona 
No. Sig 
SNPs 
Eur-anc/
Multi-ancb
Lead SNPc Positiond  Nearby genese Allelef (R/E)  EAFg OR (95%CI)h Prandomi Phetj  OR (95%CI)h Prandomi Phetj 
New asthma susceptibility loci        
5q31.3 0 / 2 rs7705042 141,492,419 NDFIP1,GNDPA1,SPRY4 C/A 0.63 1.08 (1.05-1.11) 1.6 x 10-6 0.07 1.09 (1.06-1.12) 7.9 x 10-9 0.11 0.53 
6p22.1 4 / 0 rs1233578 28,712,247 GPX5, TRIM27 A/G 0.13 1.11 (1.07-1.15) 5.3 x 10-9 0.82 1.09 (1.05-1.12) 5.9 x 10-7 0.56 0.003 
6q15 26 / 26 rs2325291 90,986,686 BACH2,GJA10,MAP3K7 G/A 0.33 0.91 (0.89-0.93) 8.6 x 10-13 0.78 0.91 (0.89-0.94) 2.2 x 10-12 0.8 0.39 
12q13.3 0 / 1 rs167769 57,503,775 STAT6,NAB2,LRP1 C/T 0.40 1.08 (1.05-1.11) 1.6 x 10-7 0.19 1.08 (1.05-1.11) 3.9 x 10-9 0.31 0.87 
17q21.33 2 / 1 rs17637472 47,461,433 ZNF652,PHB G/A 0.39 1.08 (1.05-1.11) 3.3 x 10-9 0.56 1.08 (1.05-1.11) 6.6 x 10-9 0.35 0.12 
New signals at loci previously associated with asthma in ancestry-specific populations  
6p21.33 34 / 34 rs3131064 30,763,893 IER3,DDR1 T/C  0.14 1.12 (1.08-1.16) 2.6 x 10-10 0.54  1.10 (1.06-1.13) 2.6 x 10-8 0.46 0.02 
10p14 0 / 1 rs2589561 9,046,645 GATA3,CELF2 A/G  0.89 0.90 (0.87-0.94) 1.4 x 10-8 0.78  0.91(0.88-0.94) 3.5 x 10-9 0.82 0.25 
Asthma signals previously reported for asthma plus hay fever  
8q21.13 0 / 16 rs12543811 81,278,885 TPD52,ZBTB10 G/A 0.66 0.93 (0.91-0.95) 3.4 x 10-8 0.47 0.92 (0.9-0.95) 1.1 x 10-10 0.54 0.24 
16p13.13 9 / 9 rs17806299 11,199,980 CLEC16A,DEXI,SOCS1 G/A 0.20 0.90 (0.88-0.93) 2.1 x 10-10 0.51 0.91 (0.88-0.94) 2.7 x 10-10 0.49 0.58 
Known asthma loci   
2q12 119 / 135 rs1420101 102,957,716 IL1RL1,IL1RL2,IL18R1 C/T 0.37 1.12 (1.10-1.15) 9.1 x 10-20 0.63 1.12 (1.09-1.15) 3.9 x 10-21 0.61 0.64 
5q22.1 28 / 21 rs10455025 110,404,999 SLC25A46,TSLP A/C 0.34 1.15 (1.12-1.18) 2.0 x 10-25 0.53 1.15 (1.12-1.18) 9.4 x 10-26 0.57 0.27 
5q31  16 / 28 rs20541 131,995,964 IL13,RAD50,IL4 A/G 0.79 0.89 (0.86-0.91) 1.4 x 10-14 0.73 0.89 (0.87-0.92) 5.0 x 10-16 0.77 0.62 
6p21.32 78 / 82 rs9272346 32,604,372 HLA-DRB1,HLA-DQA1 G/A 0.56 1.16 (1.13-1.19) 4.8 x 10-28 0.46 1.16 (1.12-1.19) 5.7 x 10-24 0.14 0.43 
9p24.1 30 / 57 rs992969 6,209,697 RANBP6,IL33 A/G 0.75 0.85 (0.82-0.88) 1.1 x 10-17 0.01 0.86 (0.83-0.88) 7.2 x 10-20 0.02 0.53 
11q13.5 3 / 4 rs7927894 76,301,316 C11orf30, LRRC32 C/T 0.37 1.10 (1.07-1.13) 3.5 x 10-11 0.38 1.10 (1.08-1.13) 2.2 x 10-14 0.56 0.48 
15q22.2 3 / 10 rs11071558 61,069,421 RORA,NARG2,VPS13C A/G 0.14 0.89 (0.85-0.92) 1.9 x 10-10 0.44 0.89 (0.86-0.92) 1.3 x 10-9 0.19 0.06 
15q22.33 13 / 13 rs2033784 67,449,660 SMAD3,SMAD6,AAGAB A/G 0.30 1.11 (1.08-1.14) 2.5 x 10-14 0.75 1.10 (1.08-1.13) 7.4 x 10-15 0.76 0.48 
17q12-21 158 / 173 rs2952156 37,876,835 ERBB2,PGAP3,C17orf37 A/G 0.70 0.86 (0.84-0.88) 7.6 x 10-29 0.55 0.87 (0.84-0.89) 2.2 x 10-30 0.52 0.35 
aCytogenetic position of the genome-wide significant SNPs (Prandom ≤10-8). bNumber of genome-wide significant SNPs in the European-ancestry/multi-ancestry meta-analyses. c All  
lead SNPs shown in this table have imputation quality scores > 0.80 in ≥ 80% of studies; these SNPs are the lead SNP in the European-ancestry meta-analysis if genome-wide significant 
otherwise they are the lead SNPs in the multi-ancestry meta-analysis d Build 37. eThe gene where eventually the SNP lies is first indicated followed by the previous gene and next gene. 
fR=reference allele /E=effect allele. gEAF=Effect allele frequency in European-ancestry populations (weighted average of allelic frequencies from individual studies). hOdds-ratios (ORs) 
were computed for the effect allele under a random-effects model. iP value for association of SNP with asthma (random-effects model). jP value for heterogeneity across studies using 
Cochran’s Q test. kP value for heterogeneity across ethnic groups. 
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 Table 2. Main characteristics of the nine loci harboring novel associations with asthma 
Regiona 
# of 
distinct 
signalsb 
Location of lead SNPc Cis-eQTLs in blood (B)  and lung tissue (L)d 
Association with allergy-
related and lung function 
phenotypese 
Association with auto-immune 
diseases and other immune-related 
traitse 
New asthma susceptibility loci 
5q31.3  1 NDFIP1 (intron) B: NDFIP1 (2.7x10-9)  IBD 
6p22.1 1 intergenic  Lung function  
6q15 1 BACH2 (intron) B: BACH2 (2.9x10-10)  MS, T1D, CD, IBD, V, IGG 
12q13.3  1 STAT6 (intron) B: STAT6 (9.8x10
-198) 
L: STAT6 (3.7x10-37) 
IgE (total, specific) 
Lung function  Pso, ISP_IFN 
17q21.33 1 intergenic B: GNGT2 (2.1x10-52) Atopic dermatitis ISP_IL2 
New asthma signals at loci previously associated with asthma in ancestry-specific populations 
6p21.33 3 intergenic 
B: IER3 (8.6x10-47), FLOT1 (9.1x10-33), 
VARS2 (3.7x10-30), MICB (6.9x10-21), 
HLA-C (4.1x10-18), MICA (7.4x10-12),  
L: CDSN (4.8x10-19), TUBB (2.3x10-16), 
HLA-A (1.9x10-13), AGPAT1 (2.4x10-12), 
HLA-C (5.6x10-12), MICA (2.5x10-9) 
IgE (total, specific), Self-
reported allergy, Atopic 
dermatitis, Lung Function 
SLE, UC, RA, IBD, BS, GD, SS, 
AS, Pso, UC, V, WBC, MoC, DS, 
HIV-1, SJS, HB, HBV, IMN, 
CD4:CD8 ratio, HIV-1C 
10p14 1 intergenic None Self-reported allergy RA, ISP_IL1B, ISPV 
Asthma signals previously reported for asthma plus hay fever 
8q21.13 1 intergenic None 
Atopic dermatitis,  
Asthma + hay fever 
Self-reported allergy 
RA 
16p13.13  1 CLEC16A (intron) B: DEXI (2x10-43) Atopic dermatitis,  Asthma + hay fever 
T1D, PBC, MS, RA, IBD, CD, 
LEP 
aCytogenetic position of the genome-wide significant SNPs (Prandom ≤10-8).b Number of distinct association signals at a locus detected by conditional analysis using the Genome-
wide Complex Trait Analysis (GCTA) software25 (Online Methods). c The protein coding genes flanking intergenic SNPs are shown in Table 1. d Cis-genes whose expression is 
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associated with lead asthma-associated SNPs or  proxies (r2≥0.8) using six eQTL databases from whole blood13,14, lymphoblastoïd cell lines12,15, monocytes26 and lung14,16; only 
genes showing the strongest associations are shown in this table (Supplementary Table 14 for details). eAssociations with other diseases are based on the GWAS catalog3: 
IBD=Inflammatory bowel diseases (Crohn’s disease), MS=multiple sclerosis, , T1D=type 1 diabetes, CD=celiac disease, V=vitiligo, IGG=IgG Glycosylation, Pso=psoriasis, 
ISP_IFN=Immune Response to Smallpox (secreted IFN-alpha),  ISP_IL2 Immune Response to Smallpox (secreted IL2), SLE=Systemic Lupus Erythematosus, UC=Ulcerative 
colitis, RA=Rheumatoid arthritis, BS=Behcet syndrome, GD=Grave’s disease, SS=Systemic sclerosis, AS=Ankylosing spondylitis, WBC=White Blood cell count, MoC=monocyte 
count, DS=Dengue shock, HIV-1=HIV-1-susceptibility, SJS=Stevens-Johnson syndrome, HB=Hepatitis B infection, HBV=Hepatitis B vaccine response, IMN=Idiopathic 
membranous nephropathy, CD4:CD8=CD4:CD8 lymphocyte ratio, HIV-1C=HIV-1 control, ISP_IL1B=Immune Response to Smallpox (secreted IL-1 beta), ISPV=Immune 
response to smallpox vaccine (IL-6), PBC=Primary biliary cirrhosis, LEP=Leprosy. 
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       Table 3. Overlap of TAGC asthma-associated SNPsa with GWAS catalog association signals by disease group 
 
Disease Groupb Number of GWAS 
catalog association 
signals 
Number of SNPs 
associated with asthma at 
Prandom≤10-4 in the multi-
ancestry meta-analysis 
Enrichment P-valuec 
 
Cardiovascular  743 20  7.8 x 10-42 
Body size and morphology 346 2 5 x 10-4 
Immune/Autoimmune 480 49 3.0 x 10-129 
Nervous system 242 4 1.4 x10-8 
Blood  594 10 1.3 x 10-19 
Neuropsychiatric  114 5 1.5 x 10-12 
Cancer  417 7 4.0 x 10-14 
Endocrine system  276 2 4 x 10-4 
Digestive system 347 16 1.4 x 10-37 
Eyes  177 2 2 x 10-4 
Respiratory system  85 2 3.6 x 10-5 
Infectious disease/Infection  104 2 5.3 x 10-5 
Urinary system 144 1 0.015 
Alcohol, smoking, and illicit 
substances 
30 0 1 
Musculoskeletal system 132 0 1 
a TAGC asthma-associated SNPs are those having Prandom≤10-4 in the multi-ancestry meta-analysis. b Diseases from the 
GWAS catalog were grouped according to the disease classification proposed by Wang et al.41 Note that the “Digestive 
system” group includes Crohn's Disease, a subtype of Inflammatory Bowel Disease. c The enrichment P-value is the 
binomial tail probability for observing the shown number of TAGC SNPs with Prandom≤10-4 among the SNPs reported in the 
GWAS catalog for a group of diseases (for example, the probability of observing 20 or more SNPs with Prandom≤10-4 among 
the 743 cardiovascular SNP is shown in the last column). We investigated 15 groups and a conservative Bonferroni 
adjusted significance threshold for enrichment is 0.05/15=0.003.
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Table 4. Enrichment of asthma risk SNPsa in promoter and enhancer marks and DNase I hypersensitivity sites  
 
Type of regulatory elementsb 
 Proportion of all cell types (blood cell types) showing 
enrichment with a given false discover rate (FDR)c  
 FDR ≤ 10% FDR ≤ 5% 
All promoter states  6% (26%) 0 
Active promoter states  13% (33%) 0 
All enhancer states  57% (100%) 43% (89%) 
Active enhancer states  66% (100%) 50% (100%) 
DNase I hypersensitivity sites  16% (50%) 12% (40%) 
aEnrichment was assessed at 16 asthma-loci identified by this study (Table 1); the 6p21.3 and 6p21.32 loci that encompass HLA 
were excluded because of the high amount of variability and LD in this region. b Enhancer and promoter states were derived from 
integrated functional genomics data of 127 ROADMAP and ENCODE reference epigenomes in various cell types (including 27 
leukocytes)27. DNase I hypersensitivity sites were identified in 51 cell types (including 10 leukocytes)27. c Empirical-P-values for 
enrichment were obtained using 10,000 Monte-Carlo simulations of random sets of SNPs matching the original set of asthma-
associated SNPs43; Benjamini-Hochberg’s FDR was calculated to correct for multiple testing (see Online Methods for more detail). 
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Legends 
 
Figure 1. Results of the European-ancestry meta-analysis across 127,669 individuals. 
(a–f) Manhattan plot (a) and regional plots for loci reaching genome-wide significance in the 
European-ancestry meta-analysis, including the 6p22.1 locus (b), the 6p21.33 locus (c), the 6q15 
locus (d), the 16p13.13 locus (e) and the 17q21.33 locus (f). The x axis presents physical distance 
in megabases (build 37.3) and the y axis presents −log10(Prandom) values for association statistics. The 
lead SNP (rsID) in the region is shown as a purple diamond; for remaining SNPs, the color indicates 
r2 with the lead SNP. In a, −log10(Prandom) values are for all SNPs passing quality control in at least 
two-thirds of the studies; the dashed horizontal line represents the genome-wide significance level 
(Prandom=10-8); the novel signals detected in the European-ancestry meta-analysis are shown in red, 
the known signals are in black and those that will reach significance in the multi-ancestry meta-
analysis are in blue. 
 
Figure 2. Results of the multi-ancestry meta-analysis across all 142,486 individuals.  
(a–e) Manhattan plot (a) and regional plots for loci reaching genome-wide significance in the multi- 
ancestry meta-analysis, including the 5q31.3 locus (b), the 8q21.13 locus (c), the 10p14 locus (d) 
and the 12q13.3 locus (e). The x axis presents physical distance in megabases (build 37.3) and the y 
axis presents −log10(Prandom) values for association statistics. The lead SNP (rsID) in the region is 
shown as a purple diamond; for remaining SNPs, the color indicates r2 with the lead SNP. In a, 
−log10(Prandom) values are for all SNPs passing quality control in at least two-thirds of the studies; 
the dashed horizontal line represents the genome-wide significance level (Prandom=10-8); the novel 
signals detected in the multi-ancestry meta-analysis are shown in red, the known signals are in black 
and those that were detected in the European-ancestry meta-analysis are in blue. 
  
Figure 3. Relationships between asthma-associated loci using GRAIL.  
Graphical representation of the connections between SNPs and corresponding genes with GRAIL 
P<0.05 (the 10p14 locus was ignored since the lead SNP could not be assigned to any gene in the region 
by GRAIL). Thicker and redder lines imply stronger literature-based connectivity. 
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